D.R.I.V.E. is a strategic framework for promoting representative enrollment in clinical trials. D.R.I.V.E. addresses safety and efficacy concerns that arise when studies are conducted in populations that do not reflect the different patient groups that treatments are intended to serve. Join Maya Birhiray, medical science liaison, to learn more about this initiative and its importance in clinical trials.

HealthTree Resources:

• HealthTree CureHub and Clinical Trial Finder
• Lymphoma Clinical Trial Articles
• HealthTree Connect Groups

Indy Hematology Education Resources:

• The DRIVE Initiative website can be accessed here.
• The DRIVE Score Calculator can be accessed here.

Let me know your thoughts on today's episode! Please share them in a comment or reach out anytime at [email protected]. 

TRANSCEND FL is a global trial assessing the efficacy and safety of the CAR T cell therapy lisocabtagene maraleucel in patients with relapsed or refractory follicular lymphoma. Join Dr. Kamdar, the lead investigator for this trial at University of Colorado Cancer Center, for this podcast to learn more. Feel free to email me with thoughts or questions on this podcast at [email protected].

For additional CAR T resources, see below.

HealthTree University:

• What is CAR-T therapy and how is this drug class used to treat follicular lymphoma? 
• What is some of the most promising research being done for follicular lymphoma?
• What are my options for treating follicular lymphoma?                

News Articles:

• Liso-cel CAR T-Cell Therapy
• CAR T-cell Therapy for Follicular Lymphoma 

101 Pages:

• What are the Treatments for Follicular Lymphoma?

Listen to this podcast with Dr. Carla Casulo and Judith Trotman to hear about some of the most exciting advancements for follicular lymphoma from the 2024 ASH Conference.

ASH News Articles:

What is ASH? https://healthtree.org/follicular-lymphoma/community/articles/what-is-the-ash-conference-dlbcl

FL Specialist Insights https://healthtree.org/follicular-lymphoma/community/articles/ash-24-fl-specialists-insights-new-treatments

Best of ASH 2024: https://healthtree.org/follicular-lymphoma/community/articles/ash-24-the-best-of-it-all

ASH Videos: 

https://healthtree.org/blood-cancer/university/courses/klLCY3gkYKWHQDry3bkZ

Let me know your thoughts on today's episode! Feel free to email me with questions, comments, or insights at [email protected]. 

Listen to this pre-recorded podcast to learn from Dr. Ehsan Malek, a hematologist oncologist at Roswell Park, about some of the major breakthroughs in CAR T therapy in 2024 and what is on the horizon in 2025.

Dr. Strati shares about trials happening at MD Anderson for DLBCL and follicular lymphoma. This includes the following:

Two completed follicular lymphoma trials: 

Phase I study of evorpacept and R2 in relapsed indolent B-NHL

Phase 2 study of acalabrutinib and R2 in previously untreated indolent B-NHL

One ongoing DLBCL trial:

Phase 2 study of loncastuximab as consolidation after CART in DLBCL

One upcoming DLBCL trial:

Phase 2 study of emapalaumab for the treatment of persistent severe cytopenia after CART in DLBCL

Dr. Melani discusses the latest updates from the VVIP, VIPOR, and VIPOR-P studies, which are clinical trials for non-Hodgkin's lymphoma. The goal of these studies is to improve the outcome for patients with relapsed or refractory lymphomas by using targeted therapy combinations. Targeted therapies block specific proteins that cancer cells need to grow and survive. The conversation also discusses these three clinical trials' design and treatment protocols.

Defining and tracking progression/remission in follicular lymphoma patients can be subjective and complicated. In this episode, we are joined by Dr. Juan Pablo Alderuccio. Dr. Alderuccio recently published his research on PET-based biomarkers in lymphoma patients. His research aims to give patients a more accurate knowledge of their lymphoma prognosis.

Thank you to our episode sponsor, Regeneron.